MFP
PTCT icon

Michael F. Price’s PTC Therapeutics PTCT Stock Holding History

Michael F. Price’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-33,000
Closed -$1.59M – 109
2015
Q2 		$1.59M Buy
+33,000
New +$1.93M 0.21% 72

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Michael F. Price's PTCT Position: Q3 2015 in Review

Michael F. Price sold out of PTC Therapeutics (PTCT) in Q3 2015, closing a stake of 33,000 shares — an estimated $1.59M sold.

Michael F. Price first reported a position in PTCT in Q2 2015 and held it in 1 quarter. The position peaked at $1.59M in Q2 2015. 157 funds tracked by Wall St. Rank hold PTCT as of Q3 2015.

  • Michael F. Price reported no remaining PTC Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Michael F. Price sold 33,000 PTC Therapeutics shares in Q3 2015, an estimated $1.59M.
  • Michael F. Price first reported a position in PTC Therapeutics in Q2 2015 and held it in 1 quarter.
  • Michael F. Price's PTC Therapeutics position peaked at $1.59M in Q2 2015.
  • 157 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2015.

Based on Michael F. Price's 13F filing for Q3 2015, filed 16 Nov 2015.